Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant QL1706 + trastuzumab + pertuzumab + nab-paclitaxel in HER2-positive breast cancer
ChiCTR2500107837Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in breast cancer, sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Total pathological complete response rate (tpCR), Serious adverse events (SAEs) and 1 more. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500107837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107837.